Key facts
- It has raised $64.6M; the latest was Later Stage VC ($14.5M) in Mar 2026.
- Notable investors include CICC Capital, Qianhai FoF, YuanBio Venture Capital, Leader Venture Capital, Vision Plus Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for AccuPulse
- ·The full record, as it builds
Funding rounds
No funding rounds for AccuPulse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AccuPulse
Developer of a pulsed field ablation (PFA) system intended to treat Atrial fibrillation (A-fib). The company's system offers a one-stop solution and system and equipment for pulse ablation of atrial fibrillation and tumors and leverages other major interventional therapies using radio frequency and cryotherapy, providing doctors and patients with a system that has better catheter localization, signal acquisition and more intelligent integration.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- accupulse.com/
- Ownership
- Privately Held (backing)
AccuPulse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AccuPulse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AccuPulse in its N-PORT filings yet. We sweep new filings monthly.